Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19)
NCT ID: NCT04393428
Last Updated: 2020-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2020-03-01
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prediction of Acute Kidney Injury in Patients With COVID-19
NCT04406688
Renal Biomarkers in AKI and COVID-19
NCT04517630
Acute Kidney Dysfunction in COVID-19 and Non-COVID-19 Related ARDS
NCT05699889
Renal Cell Arrest and Damage Biomarkers in Progression and Outcome of Septic AKI
NCT06064487
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
NCT04491227
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 patients with urinary samples
COVID-19 patients with urinary samples
[TIMP-2]*[IGFBP-7]
\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[TIMP-2]*[IGFBP-7]
\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COVID-19 confirmed by positive SARS-CoV-2 PCR
* at least one urine sample
Exclusion Criteria
* Paritcipation rejections
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Romaric Larcher, MD, PharmD, MSc
Role: PRINCIPAL_INVESTIGATOR
UH Montpellier
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Uhmontpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL20_0294
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.